Empagliflozin Approval May Come This Year After Boehringer Resolves GMP Problems

BI/Lilly’s SGLT-2 inhibitor is to be manufactured in a facility that was subject to a May 2013 warning letter from FDA.

More from Archive

More from Pink Sheet